Viome Life Sciences
PrivateLast Round
Series D
Sep 10, 2024
Est. Valuation
$339M
Total Funding Raised
$337.5M
Company Overview
Viome Life Sciences is a biotechnology company that provides at-home health tests analyzing microbial and human gene expressions to offer personalized nutrition and supplement recommendations.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, D2C Brands, Subscription Commerce
Business Model
B2C
Customer Profile
Subscription SaaS, Hardware Sales
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Viome Life Sciences Comparables
Compare Viome Life Sciences with similar companies based on industry and business-model similarity.
Viome Life Sciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Sep 10, 2024 | ||||
| Series C Extension | Aug 18, 2023 | ||||
| Series C | Oct 18, 2022 | ||||
| Convertible Debt | Nov 10, 2021 | ||||
| Debt | Feb 10, 2021 | ||||
Series B | Nov 27, 2019 |
Viome Life Sciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ocgrow Ventures | Convertible Debt, Series C |
| Ezaki Glico Co., Ltd. | Convertible Debt, Series B, Series C |
| Khosla Ventures | Convertible Debt, Series B, Series D, Series B Extension, Series C, Series A, Series C Extension |
| Bold Capital Group | Convertible Debt, Series B, Series C |
| WRG Ventures | Series D, Series C Extension |
| WestRiver Group | Convertible Debt, Series C |
| BOLD Capital Partners | Series A, Series B, Series D, Series C Extension, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 1, 2026
Added Ketch Kloud, Inc. (Technology/Data Privacy) as a customer.
- Jul 18, 2025
Integration to leverage secure and scalable infrastructure services.
Recent news
Latest coverage and updates
- launchesOct 9, 2026
Viome Life Sciences, Inc. launches CancerDetect Pancreatic
- hiresAug 16, 2026
Viome Life Sciences, Inc. hired Younggren as president on Aug 16th '26.
- acquiresAug 13, 2026
Viome Life Sciences, Inc. acquired Circulate Health Inc. for $15M on Aug 16th '26.
Viome Life Sciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Viome Life Sciences's valuation, stock price, and market status.
Is Viome Life Sciences a public or private company?
Viome Life Sciences is a private company.
What is the current stock price of Viome Life Sciences?
Viome Life Sciences is a private company, so its shares have no public market price. Caplight tracks Viome Life Sciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Viome Life Sciences worth (valuation)?
Viome Life Sciences's valuation is estimated at $339.0M based on funding round data.
Can I buy Viome Life Sciences stock?
Viome Life Sciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Viome Life Sciences's last funding round?
Viome Life Sciences's most recent funding round was Series D on September 10, 2024.
Who are the main investors in Viome Life Sciences?
Key investors in Viome Life Sciences include Khosla Ventures, Bold Capital Group, BOLD Capital Partners, Bold Capital.
Will Viome Life Sciences IPO soon?
No public IPO plans have been announced for Viome Life Sciences.
How can I track Viome Life Sciences secondary market activity?
Caplight tracks bids, offers, and trades in Viome Life Sciences's shares on secondary markets.